Drug Profile
Research programme: gamma-butyrobetaine hydroxylase inhibitors - Grindeks
Alternative Names: GBB hydroxyls inhibitors - GrindeksLatest Information Update: 28 May 2018
Price :
$50
*
At a glance
- Originator Grindeks
- Class Small molecules
- Mechanism of Action Mixed function oxygenase inhibitors; Partial fatty acid oxidation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 May 2018 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Latvia
- 01 Apr 2014 Preclinical trials in Cardiovascular disorders in Latvia (unspecified route)